FDA agrees to review generics from Sandoz and Hybio, signaling new competition in the weight-loss market against Eli Lilly.
1 report, 1 independent
Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
FDA agrees to review generics from Sandoz and Hybio, signaling new competition in the weight-loss market against Eli Lilly.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Sandoz
organization
Nothing else this week.
- FDA
-
Eli Lilly and Company
American pharmaceutical company
Related events
- FDA approved tirzepatide for diabetes and obesity, amid competition between Eli Lilly and Novo Nordisk in the GLP-1 market.
- Eli Lilly and Company plans to submit a drug candidate to the FDA for review and approval.
- Lilly and Novo Nordisk are competing in the weight loss drug market, with Lilly expanding its US market coverage.
- Eli Lilly's Tirzepatide is driving 65% of the company's revenue amid intense competition in the GLP-1 market.
- Eli Lilly and Novo Nordisk are facing scrutiny regarding their name-brand weight loss drugs due to findings during an FDA data review.